Clinical Trial Update: Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating efficacy and safety of 3.0 mg liraglutide for weight regain after Roux-en-Y gastric bypass; results posted 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: NYU Langone Health | Conditions: Obesity | Phase 4 | Status: COMPLETED | Results posted: 2022-03-22